Share on LinkedInShare on LinkedIn

ARTICLE · 24 AUGUST 2018

Brexit And Life Sciences Update

Mishcon de Reya LLP
Mishcon de Reya LLP
Contributor
Mishcon de Reya LLP

Mishcon de Reya LLP

Founded by Lord Mishcon in 1937, in a one-room office in Brixton, Mishcon de Reya now employs over...

View firm profile
Explore more from Mishcon de Reya LLP

We last reported on Brexit developments in the May 2018 edition where we focused on the resounding message that the industry still had to prepare for a hard Brexit,

United KingdomGovernment, Public Sector

We last reported on Brexit developments in the May 2018 edition where we focused on the resounding message that the industry still had to prepare for a hard Brexit, whilst hoping for an agreement incorporating an implementation period to allow breathing room to adjust to the post-Brexit position, and for bespoke arrangements to be made on certain key issues. These could include perhaps the UK's continued membership of the EMA, with a majority of MPs voting in July that the UK should negotiate for this. As we approach the October deadline for an agreed position on the draft withdrawal agreement, a number of important statements and reports have been issued.

MHRA Statements

In early August, the MHRA issued a series of statements intended to allay the fears of industry in relation to certain aspects. However, the statements are all premised on the basis that an agreement will be reached which includes the implementation period until the end of 2020. By failing to

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from